Q2 2025 Merck & Co Inc Earnings Call Transcript

Jul 29, 2025 / 01:00PM GMT

Release Date Price: C$18.91 (-1.56%)

Transcript 10-Q8-K

Key Points

Positve

Merck & Co Inc (MRK) reported Q2 2025 revenue of $15.8 billion, reflecting strong performance in oncology and animal health.
The company announced the acquisition of Verona Pharma, enhancing its pipeline with Ohtuvayre, a novel treatment for COPD.
Merck & Co Inc (MRK) is conducting over 80 Phase 3 studies across various therapeutic areas, indicating a robust pipeline.
The FDA approved ENFLONSIA for RSV prevention in infants, showcasing regulatory success and expanding the vaccine portfolio.
WINREVAIR achieved $1 billion in cumulative sales within 15 months of launch, demonstrating strong market uptake and execution.

Negative

Total company revenues decreased by 2% due to a significant decline in GARDASIL sales in China, impacting overall growth.
The company faces challenges with elevated GARDASIL inventories in China, leading to a halt in shipments for the remainder of 2025.
Merck & Co Inc (MRK) anticipates a negative impact from foreign exchange on full-year revenue and EPS guidance.
The company is experiencing competitive pressures in the vaccine segment, particularly in Japan, affecting sales growth.
Operating expenses increased, including a $200 million charge related to a license agreement, impacting profitability.

Operator

Thank you for standing by. Welcome to the Merck & Company, Inc., Rahway, New Jersey, USA Q2 sales and earnings conference call. (Operator Instructions) This call is being recorded. If you have any objections, you may disconnect at this time.

I would now I turn the conference over to Mr. Peter Dannenbaum, Senior Vice President, Investor Relations. Sir, you may begin.

Peter Dannenbaum

Merck & Co Inc - Senior Vice President, Investor Relations

Thank you, Shirley, and good morning, everyone. Welcome to the second-quarter of 2025 conference call for Merck & Company, Incorporated, Rahway, New Jersey, USA. Speaking on today's call will be Rob Davis, Chairman and Chief Executive Officer; Caroline Litchfield, Chief Financial Officer; and Dr. Dean Li, President of Research Labs.

Before we get started, I'd like to point out that we have items in our GAAP results such as acquisition-related charges, restructuring costs, and certain other items that we have excluded from our non-GAAP results. There is a reconciliation in our press release.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.